Pricing

Xencor Inc (XNCR)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Bassil I. Dahiyat
Employees: 280
Web site: xencor.com
465 N. HALSTEAD ST., SUITE 200, PASADENA, CA, 91107
626-305-5900
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Xencor, Inc. focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available